Guided surgery for medullary thyroid cancer using advanced imaging

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of 68Ga-labeled targeted covalent radiopharmaceutical (TCR) fibroblast activation protein inhibitor (FAPI) PET/CT in guiding surgical treatment for medullary thyroid carcinoma (MTC). The study aims to improve surgical outcomes by accurately mapping the extent of MTC lesions, which is crucial for effective treatment. Patients will be categorized into three groups based on their diagnosis and surgical indications, with the primary endpoint being the calcitonin level one month post-surgery. Secondary endpoints include event-free survival and the accuracy of the imaging technique in identifying MTC lesions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age between 18 and 75 years；
* Diagnosed with MTC and have surgical indication based on preliminary evaluation; the tumor may be newly diagnosed or previously treated;
* Expected survival of at least 12 weeks;
* No major organ dysfunction (heart, lung, liver, kidney and other major organ include), acute or life-threatening status of infection;
* Be willing and able to understand the research content and provide written informed consent/assent for the trial.

Exclusion Criteria:

* Have a history of imaging agent allergies;
* Does not meet the PET-CT scan sedation requirements, or has contraindications for PET-CT examination;
* Be pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial;
* No surgical indication (i.e., no measurable disease, unresectable disease, or significant present of distant metastasis), refusing surgery or 68Ga-TCR-FAPI PET/CT-guided surgery.

Where it's running

• National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
  Beijing, China Recruiting

Study contacts

• Study coordinator: Shaoyan Liu, M.D.
• Email: shaoyanliu.bj@263.net
• Phone: 0086-010-87787190

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Radiation plus tarlatamab for DLL3-expressing tumors

  This trial will test whether giving tarlatamab together with standard palliative or consolidative radiation is safe for adults with DLL3-expressing or DLL3-prevalent tumors such as melanoma, medullary thyroid cancer, sinonasal undifferentiated carcinoma, esthesioneuroblastoma, and bladder cancer.

  Recruiting at 3 sites Phase 1/2 University of Arizona · Gilbert, Arizona and 2 other locations · NCT06814496

• Evaluating FAPI PET for diagnosing pleural mesothelioma

  This study is testing a new type of imaging called FAPI PET/CT to see if it can better diagnose pleural mesothelioma in patients compared to standard imaging methods.

  Recruiting Phase 2 Aalborg University Hospital · Aalborg, Region North Jutland · NCT06790082

• Understanding genetic causes of neuroendocrine tumors in Mexican patients

  This study is trying to find out the genetic changes that cause neuroendocrine tumors in Mexican patients to help develop better treatments.

  Recruiting at 3 sites Universidad Nacional Autonoma de Mexico · Mexico City, Mexico City and 2 other locations · NCT06523582

• Personalized mRNA vaccine for advanced endocrine tumors

  This study is testing a personalized mRNA vaccine to see if it can help patients with advanced endocrine tumors who haven't had success with standard treatments.

  Recruiting Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT06141369

• Evaluating Anlotinib for Advanced Medullary Thyroid Cancer

  This study is testing whether Anlotinib can help people with advanced medullary thyroid cancer feel better and manage their disease more effectively.

  Recruiting at 15 sites Phase 4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 18 other locations · NCT05830500

• Using 68Ga-FAPI PET/CT to visualize malignant tumors

  This study is testing a new imaging method using a special agent to see if it can help doctors better spot and understand malignant tumors, especially in gastrointestinal cancers.

  Recruiting Zhongnan Hospital · Wuhan, Hubei · NCT05034146

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.